Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.

Real-time index price for S&P Midcap 400 (IDX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs We may not be alone in the universe: ...

A 4.1 magnitude earthquake rattled eastern Tennessee and was felt all through the Southeastern states. 'The Big Weekend Show' panelists discuss President Donald Trump's new announcement.

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country in November 2023, more than two years after Wegovy, made ...

The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...